Occupational health is the refl ection of this defi nition in working life. Occupational diseases originating from psychosocial factors confront us as the result of risks faced in workplace and have a negative impact on employees' productiveness, peace, and health. All these factors infl uence labor peace negatively. This issue has psychological, legal, and economic aspects. Though occupational health and safety is of particular concern to employees, employers, society, and national economy, psychological occupational diseases have quite a limited coverage in literature. Based on the explanations made above, the present study will concretely present the psychosocial risk factors emerging in the unique structure of working life in Turkey in the fi rst place. Then problems associated with psychological occupational diseases resulting from psychosocial risk factors that are experienced by employees will be analyzed based on responses to the survey form developed. After the results are evaluated, it will be possible to develop policies about methods of fi ghting with the problems caused by psychological occupational diseases in workplace, family, and society. It will be showed that if appropriate measures are taken on this subject, effi ciency and productivity in workplace can be increased by supporting employees exposed to psychosocial risks in workplace through corporate and legal arrangements. It is considered that the present study will considerably improve the awareness of all parties concerned with the issue.

Introduction: A higher percentage of sustained virologic response (SVR) has been reported with the introduction of direct-acting antivirals (DAAs) to the treatment of hepatitis C in recent years. However, there are still relatively limited data on the effectiveness and safety of the use of DAAs in hemodialysis patients. The aim of this study was to evaluate the efficacy and safety of chronic hepatitis C treatment with paritaprevir/ritonavir/ ombitasvir and dasabuvir (3D) in hemodialysis patients. Materials and Methods: Hemodialysis patients who were treated with 3D regimen between July 2016 and October 2018 were evaluated retrospectively. Patients coinfected with hepatitis B or human immunodeficiency virus and those with cirrhosis were excluded. Serum hepatitis C virus (HCV) RNA and alanine aminotransferase levels of the patients were recorded after one and three months of therapy. SVR was defined as negative HCV RNA at three months after cessation of HCV treatment. Any drug-related alterations in clinical or laboratory findings during the treatment period were evaluated as side effects. Results: Fifteen patients who were treated with the 3D regimen during the study period were included. Genotype 1b and 1a were detected in 12 and three patients, respectively. Ribavirin was added to treatment for genotype 1a-infected patients. Hemoglobin levels were reduced in two of the three patients who received ribavirin. One patient had macular rash and another patient complained of fatigue. No serious side effects were observed. At the end of treatment, a low level of HCV RNA (63 IU/ml) was detected in only one patient. At the end of treatment, HCV RNA negativity was achieved in 12 out of 13 patients whose HCV RNA quantitation data were available. End-of-treatment success rate was 92%. SVR was achieved in all of the patients at three-months after treatment cessation (100% SVR12). Conclusion: This study shows that the 3D regimen is safe and effective in the treatment of hemodialysis patients infected with hepatitis C.